Literature DB >> 18316028

Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.

Won-il Jeong1, Douglas Osei-Hyiaman, Ogyi Park, Jie Liu, Sándor Bátkai, Partha Mukhopadhyay, Norio Horiguchi, Judith Harvey-White, Giovanni Marsicano, Beat Lutz, Bin Gao, George Kunos.   

Abstract

Alcohol-induced fatty liver, a major cause of morbidity, has been attributed to enhanced hepatic lipogenesis and decreased fat clearance of unknown mechanism. Here we report that the steatosis induced in mice by a low-fat, liquid ethanol diet is attenuated by concurrent blockade of cannabinoid CB1 receptors. Global or hepatocyte-specific CB1 knockout mice are resistant to ethanol-induced steatosis and increases in lipogenic gene expression and have increased carnitine palmitoyltransferase 1 activity, which, unlike in controls, is not reduced by ethanol treatment. Ethanol feeding increases the hepatic expression of CB1 receptors and upregulates the endocannabinoid 2-arachidonoylglycerol (2-AG) and its biosynthetic enzyme diacylglycerol lipase beta selectively in hepatic stellate cells. In control but not CB1 receptor-deficient hepatocytes, coculture with stellate cells from ethanol-fed mice results in upregulation of CB1 receptors and lipogenic gene expression. We conclude that paracrine activation of hepatic CB1 receptors by stellate cell-derived 2-AG mediates ethanol-induced steatosis through increasing lipogenesis and decreasing fatty acid oxidation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316028     DOI: 10.1016/j.cmet.2007.12.007

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  116 in total

Review 1.  Hepatic stellate cells and innate immunity in alcoholic liver disease.

Authors:  Yang-Gun Suh; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  New Approaches for Studying Alcoholic Liver Disease.

Authors:  Jun Xu; Xiao Liu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2014-09-14

Review 3.  Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease?

Authors:  Wonhyo Seo; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 4.  The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver.

Authors:  Robin D Clugston; Madeleine A Gao; William S Blaner
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 5.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

6.  Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors.

Authors:  Gábor Turu; Péter Várnai; Pál Gyombolai; László Szidonya; László Offertaler; György Bagdy; George Kunos; László Hunyady
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

Review 7.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

8.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

Review 9.  The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Authors:  Martin E Cooper; Simon E Regnell
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 10.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.